Benzodiazepines act at the level of the limbic, thalamic, and hypothalamic regions of the CNS, and can produce any level of CNS depression required including sedation, hypnosis, skeletal muscle relaxation, anticonvulsant activity, and coma. The action of these drugs is mediated through the inhibitory neurotransmitter gamma-aminobutyric acid (GABA). Central benzodiazepine receptors interact allosterically with GABA receptors, potentiating the effects of GABA and thereby increasing the inhibition of the ascending reticular activating system. Benzodiazepines block the cortical and limbic arousal that occurs following stimulation of the reticular pathways.
Moreover, Clonazepam is able to suppress the spike and wave discharges in absence seizures and decrease the frequency, duration, amplitude and spread of discharge in minor motor seizures.
Clonazepam appears in the following formations and dosage:
Tablets: 0.5 mg, 1 mg and 2 mg
Tablets Disintegrating: 0.125 mg, 0.25 mg, 0.5 mg, 1 mg and 2 mg
General data on Clonazepam Active Pharmaceutical Ingredient
CAS Registry: 1622-61-3
ATC: N03AE01
Molecular Formula: C15H10ClN3O3
Molecular Weight: 315.7
Pharmacopoeias: In Chin., Eur., Jpn, and US.
TAPI's Clonazepam Pharmaceutical Ingredient
TAPI's Clonazepam Active Pharmaceutical Ingredient is produced in Assia Chemical Industries Limited - Teva Tech site in Beer Sheva, Israel.
Clonazepam is produced by TAPI by Organic synthesis and considered to be low-medium volume Active Pharmaceutical Ingredient.
